<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560323</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20180077H</org_study_id>
    <nct_id>NCT03560323</nct_id>
  </id_info>
  <brief_title>Understanding the Cardiovascular Benefits of the Anti-Diabetes Medication SGLT2 Inhibitors</brief_title>
  <official_title>SGLT2 Inhibitors, Ketones, &amp; Cardiovascular Benefit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels,
      spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i)
      parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac
      magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission
      tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class
      II-III New York Heart Association (NYHA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose/Objectives The EMPA-REG OUTCOME (NCT01131676) trial demonstrated that SGLT2
      (sodium-glucose co-transporter) inhibition with empagliflozin markedly reduced cardiovascular
      (CV) mortality and hospitalization for heart failure. In diabetic patients treated with SGLT2
      inhibitors, a rise in plasma ketone concentration consistently has been observed. This has
      led to the &quot;ketone hypothesis&quot; in which a shift from glucose/FFA (Free Fatty Acids) to ketone
      utilization by the heart results in enhanced left ventricular systolic/diastolic function and
      could, at least in part, explain the reduction in CV mortality and hospitalization for heart
      failure observed in the EMPA-REG OUTCOME trial.

      Methods 36 type 2 diabetic subjects with New York Heart Association (NYHA) Class II-III heart
      failure and ejection fraction less than 50% will be studied. Eligible subjects will undergo a
      baseline cardiac MRI to obtain quantitative measures of baseline cardiac functional
      parameters: chamber volumes and pressures, wall thickness, LV diastolic function (E/A ratio,
      peak LV filling rate, diastolic volume), LV systolic function (cardiac output, stroke volume,
      systolic volume, peak LV ejection rate). Baseline samples will be drawn for measurement of
      N-terminal pro-brain natriuretic peptide (NT-proBNP) , B-OH-butyrate, acetoacetate, glucose,
      FFA, lactate, pyruvate, glycerol, HCO3 (bicarbonate), insulin, glucagon, renin and
      aldosterone. Following completion of the baseline MRI and blood samples, subjects will be
      divided into three groups (12 subjects per group). Each group will receive a 6-hour (3-hour
      in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to
      7.4) to increase the plasma B-OH-B concentration by ~0.5, ~2.0, and ~5.0 mmol/L. At the end
      of the infusion the MRI will be repeated. As a time control GROUP II subjects will receive a
      continuous infusion of sodium bicarbonate (0.12 M) for 6 hours (0.08 mg/kg/min) to mimic the
      rise in plasma bicarbonate concentration observed with B-OH-B infusion. Group II will return
      again to the RII (UT Health Research Imaging Institute) on a separate day for a cardiac
      positron emission tomography (PET) study to examine the effect of hyperketonemia on
      myocardial glucose uptake and blood flow. In ~14 days subjects will return for a repeat
      PET/18F-2-DOG (deoxyglucose) study with one exception: NaHCO3 (Sodium bicarbonate) will be
      infused instead of B-OH-B. The two studies will be performed in random order.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>36 type 2 diabetic subjects with New York Heart Association (NYHA) Class II-III heart failure and ejection fraction &lt;50% (documented by patient's medical records with an Echocardiogram (ECHO) or any other heart imaging) will be studied. Other inclusion criteria: age = 30-70 years; BMI =23-38 kg/m2; 18 males/18 females; HbA1c = 6.0-9.0%; BP &lt; 145/85 mmHg; Estimated glomerular filtration rate (eGFR) &gt; 45 ml/min•1.73 m2. Subjects must have an NT-proBNP ≥ 500 pg/ml (or ≥ 300 pg/ml if ejection fraction is less than 35 %) and be on a stable dose of guideline-directed heart fail medication (i.e. ACE inhibitor (ACEI), Angiotensin II receptor blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), beta blocker, diuretic and/or mineralocorticoid receptor antagonist). Patients must be on stable antihypertensive therapy for at least 2 months. Only diabetic subjects treated with diet/exercise, metformin monotherapy, sulfonylurea monotherapy (SU) or combination metformin/SU therapy.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>300-360 minutes after the start of infusion</time_frame>
    <description>Parameters of left ventricular (LV ) diastolic and systolic function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial energetics</measure>
    <time_frame>300-360 minutes after the start of infusion</time_frame>
    <description>Myocardial glucose uptake</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Heart Failure</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group I Beta-Hydroxy-Butyrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II Beta-Hydroxy-Butyrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III Beta-Hydroxy-Butyrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-hydroxy-butyrate</intervention_name>
    <description>Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (12 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.
GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end</description>
    <arm_group_label>Group I Beta-Hydroxy-Butyrate</arm_group_label>
    <arm_group_label>Group II Beta-Hydroxy-Butyrate</arm_group_label>
    <arm_group_label>Group III Beta-Hydroxy-Butyrate</arm_group_label>
    <other_name>Infusion of Beta-Hydroxy-Butyrate (B-OH-B)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes.

          2. Class II-III New York Heart Association (NYHA) heart failure with ejection fraction
             less than 50 %.

          3. Age 30-70 years.

          4. BMI 23-28 kg/m2.

          5. 18 males/18 females.

          6. HbA1c 6.0-9.0 %.

          7. Blood pressure &lt; 145/85 mmHg.

          8. eGFR &gt; 45 mL/min/1.73 m2.

          9. NT-proBNP ≥ 500 pg/mL (or ≥ 300 pg/mL if ejection fraction is less than 35 %).

        Exclusion Criteria:

          1. Treatment with Glucagon-like peptide-1 receptor agonist (GLP-1 RA), Dipeptidyl
             peptidase-4 inhibitors (DPP4i), pioglitazone, SGLT2 inhibitor or insulin.

          2. Women who are pregnant or breastfeeding.

          3. Contraindications for MRI include metal plates, parts, screws, shrapnel, pins in the
             body, or cardiac pacemaker.

          4. Any other condition that in the opinion of the investigator create a hazard to the
             subject safety, endanger the study procedures or interfere with the interpretation of
             study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph A. DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolina Solis-Herrera, MD</last_name>
    <phone>210-358-7200</phone>
    <email>solisherrera@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Diabetes Institute - University Health System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Solis-Herrera, MD</last_name>
      <phone>210-358-7200</phone>
      <email>solisherrera@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Qin, MD</last_name>
      <phone>210-358-7200</phone>
      <email>qiny@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Henri Honka, MD PhD</last_name>
      <phone>210-567-6691</phone>
      <email>honka@uthscas.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketone Body Metabolism</keyword>
  <keyword>Myocardial Glucose Uptake</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>Myocardial Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

